CanSOLVE CKD has hosted 2 training workshops to help enable a truly effective and meaningful partnership. To date, 56 network members have received training in patient-oriented research at sessions facilitated by CanSOLVE CKD. Core Infrastructure The network’s sustainability plan includes creating core national infrastructure for research, KT, and training. The national KT network for patients with kidney failure (www. cann-net.ca) will be expanded, as will the scope of a national network of multidisciplinary CKD clinics.16 These resources will be key to disseminating results of Can-SOLVE CKD studies. A repository for biosamples across diabetes, glomerulonephritis, and polycystic kidney disease17-19 will be created to support collaborative research. Current research training programs will grow. All resources will be united to create core infrastructure that is greater than the sum of its parts (Table 3). Table 1. Can-SOLVE CKD Research Themes, Priorities, and Projects. Research themes Research priorities Research projects Theme 1: Identify kidney disease earlier and support those who are at highest risk of negative outcomes Priority 1.1: How can we identify those with or at risk for CKD earlier? 1.1A: Improving renal complications in adolescents with type 2 diabetes through research (iCARE) 1.1A: Assessment of early markers of cardio-renal risk in a longitudinal cohort of youth with diabetes (AdDIT) 1.1B: Identifying diabetes and CKD in Indigenous communities Priority 1.2: How can we identify and treat those at highest risk for progression to kidney failure? 1.2: Defining risk and personalizing treatment of patients with glomerulonephritis and autosomal dominant polycystic kidney disease 1.2: Glomerulonephritis translational research program Priority 1.3: How can we identify those at highest risk for adverse outcomes? 1.3A: Integrating risk-based care for patients with CKD in the community 1.3B: Risk prediction to support shared decision making for managing heart disease (APPROACH) Theme 2: Define best treatments to improve outcomes and quality of life Priority 2.1: What are the best treatments to improve outcomes for patients with CKD? 2.1A: Cell therapy for advanced diabetic kidney disease 2.1A: Clinical trials of promising repurposed drugs/ compounds for autosomal dominant polycystic kidney disease 2.1B: Aldosterone inhibition and enhanced toxin removal in hemodialysis patients (ACHIEVE) Priority 2.2: What strategies can reduce symptom burden in patients with advanced CKD? 2.2: Dialysis symptom control (DISCO) 2.2: Etiology of pruritus during dialysis 2.2: Patient-reported outcomes clustered RCT (EMPATHY) Theme 3: Define the optimal ways to deliver patient-centered care in the 21st century Priority 3.1: What model of care will best deliver evidence-based personalized care? 3.1A: Restructuring kidney care to meet the needs of 21stcentury patients 3.1B: Targeted de-prescribing in patients with CKD to decrease polypharmacy Priority 3.2: How can we better enable selfmanagement of CKD, where appropriate? 3.2: Strategies to enhance patient self-management of CKD Priority 3.3: What is the best way to help patients access the best treatment for their kidney failure? 3.3A: Improving patient knowledge about treatment options 3.3B: Increasing the use of living donor kidney transplantation Note. Can-SOLVE CKD = Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease; CKD = chronic kidney disease; AdDIT = Adolescent type 1 Diabetes cardio-renal Intervention Trial; RCT = randomized controlled trial. 6 Table 2. Examples of Selected Can-SOLVE CKD Research Projects. Project Lead(s) Issue Research plan 1.1B: Identifying diabetes and chronic kidney disease in Indigenous communities Dr Paul Komenda Dr Adeera Levin Indigenous people in Canada are at high risk for CKD and progression to end-stage kidney disease. Current evidence shows Indigenous people progress to end-stage kidney disease 10 years earlier than non-Indigenous people. If CKD is detected early, progression can be delayed through earlier treatment. However, as many Indigenous people live in rural and remote communities, they face additional barriers to accessing appropriate screening, detection, and treatment. This project will address inequities in access to CKD and diabetes diagnosis and treatment among Indigenous people across Canada, which is one of the top research priorities identified by patients and stakeholders. It has the potential to fundamentally change health care delivery for Indigenous Canadians living in remote communities who are at very high risk of diabetes and CKD. The experienced project team, based at the University of Manitoba, has piloted point-of-care screening in Manitoba Indigenous communities. They will apply their screening strategy to communities in British Columbia, Alberta, Saskatchewan, Ontario, and other areas within Manitoba. The goal is to screen 4000 individuals. 3.3B: Increasing the use of living donor kidney transplantation Dr Amit X. Garg Despite the advantages of kidney transplantation over dialysis (ie, improved survival and quality of life, substantial savings to the health care system), only about 40% of Canadians with end-stage renal disease are treated with a kidney transplant. The best way to improve access to kidney transplantation is unknown. There are too few deceased donors to meet the demand for